Board Change

Sareum Holdings PLC
19 October 2006


For immediate release                                           19 October 2006



                              SAREUM HOLDINGS PLC

                          ("Sareum" or "the Company")



                                  Board Change

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, announces today that Alan Lamont has stepped down from the Board with
immediate effect. Dr Lamont has recently been appointed as Director of Science
and Technology Alliances at AstraZeneca and felt that he could not combine his
new responsibilities with his position as a director of Sareum.

The Board of Sareum would like to thank Dr Lamont for his considerable
contribution to the Company during its formative years.



For further information please contact:


Sareum Holdings                                            [phone]

Tim Mitchell, Chief Executive Officer

Buchanan Communications                                    [phone]

Tim Anderson, Mary-Jane Johnson

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. Sareum Limited was formed in August 2003 to discover new drugs
for the treatment of cancer and to provide a range of drug discovery services to
the pharmaceutical industry. Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.



A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease. Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression. Knowledge of the
structure of the potential drugs and how they 'lock-in' to the protein permits
the best potential drug to be discovered. Determining structure is a complex
task and requires leading-edge equipment and experienced staff. Sareum's
approach to structure determination is to produce multiple recombinant proteins
primarily through a baculovirus expression system and to determine their
structure using x-ray crystallography.



When the structure is determined, the Company's innovative Template Screening
platform is used to identify novel chemical starting material designed to
interact with the target protein. Sareum then uses its high-throughput medicinal
chemistry platform to rapidly optimise these molecules and develop the most
promising into potential drug candidates.



Sareum provides its specialist drug discovery capabilities to partners in the
pharmaceutical and biotechnology industries. The Company aims to successfully
deliver: Programmes for complete gene-to-candidate structure-based discovery;
projects to accelerate or improve the productivity of specific activities; and
drug candidates for licensing at the Phase I or Phase II clinical trials stage.



Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange